Consensus ESG Ratings
Member Sign In
ESG News For ImmunoGen, Inc.
These sites contributed news to this page:
-
The Dion Foundation and Atamyo Therapeutics Announce a Partnership to Expand into the US Atamyo’s Clinical Trial of ATA-200 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5
The Dion Foundation for Children with Rare Diseases will finance expansion in the US of Atamyo’s first-in-human trial of ATA-200.The Phase 1b, dose-escalation study to evaluate the safety and efficacy of ATA-200 in children has already received regulatory clearance in Europe.ATA-200 is a single-injection gene therapy aimed to treat limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5) caused by mutations in the g-sarcoglycan gene